Skip to main content
Top
Published in: Clinical Rheumatology 12/2013

01-12-2013 | Original Article

Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus

Authors: Gaixiu Su, Zuo Luan, Fengqi Wu, Xinning Wang, Xiangfeng Tang, Nanhai Wu, Kai Wang

Published in: Clinical Rheumatology | Issue 12/2013

Login to get access

Abstract

This study attempts to evaluate the outcome of autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT) in patients with severe paediatric systemic lupus erythematosus (SLE). Five patients (n = 2 females, n = 3 males) with severe or refractory paediatric SLE received autologous peripheral blood CD34+ cell transplants between July 2005 and February 2009. The patients ranged in age from 6 to 14 years, and the course of disease extended over a period from 5 to 90 months. All of the patients received conventional therapy for 3 to 87 months. After their discharge from the hospital, the patients continued to maintain their regular follow-up visits and basic quality of life. The patients exhibited decreased immune function after the auto-PBHSCT. The CD4+ and CD19+ cells were significantly reduced. Viremia occurred in four patients 2 months after the transplantation. All of the patients went into clinical remission in 3–6 months. The severity of encephalopathy, nephritis and organ damage declined in varying degrees. The disease recurred in patient 2 at 9 months and in patient 4 at 12 months after the transplantation. Because the disease was relatively mild, we were able to administer small doses of glucocorticoids that were sufficient to control the course of the disease. Macrophage activation syndrome occurred in patient 3 at 18 months after the transplantation. At the end of the follow-up period, three of the five patients were completely off their medications. Another two patients sustained small doses of glucocorticoids. The developmental levels of these patients were comparable to those of normal children at the end of the follow-up. The quality of life improved significantly. The auto-PBHSCT is effective for severe and refractory paediatric SLE. The incidence of lethal infection and other adverse reactions is low. Long-term remission can be achieved. A milder form of the disease may have recurred after the transplantation.
Literature
1.
go back to reference Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED (2008) Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152(4):550–556PubMedCrossRef Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED (2008) Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152(4):550–556PubMedCrossRef
2.
go back to reference Stichweh D, Arce E, Pascual V (2004) Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 16(5):577–587PubMedCrossRef Stichweh D, Arce E, Pascual V (2004) Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 16(5):577–587PubMedCrossRef
3.
go back to reference Tyndal A, Gratwohl A (1997) Blood and marrow stem cell transplantation in autoimmune disease: a consensus report written on behalf of the European League against Rheumatism and the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 19:643–645CrossRef Tyndal A, Gratwohl A (1997) Blood and marrow stem cell transplantation in autoimmune disease: a consensus report written on behalf of the European League against Rheumatism and the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 19:643–645CrossRef
4.
go back to reference Marmont AM (1998) Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 83(8):733–743PubMed Marmont AM (1998) Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 83(8):733–743PubMed
5.
go back to reference Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK (2000) Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356(9231):701–707PubMedCrossRef Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK (2000) Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356(9231):701–707PubMedCrossRef
6.
go back to reference Tyndall A (2001) Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus. Lupus 10(3):214–215PubMedCrossRef Tyndall A (2001) Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus. Lupus 10(3):214–215PubMedCrossRef
7.
go back to reference Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. Lancet 357(9261):1027–1032PubMedCrossRef Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. Lancet 357(9261):1027–1032PubMedCrossRef
8.
go back to reference Wulffraat NM, Sanders LA, Kuis W (2000) Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2(4):316–323PubMedCrossRef Wulffraat NM, Sanders LA, Kuis W (2000) Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2(4):316–323PubMedCrossRef
9.
go back to reference Wu FQ, Luan Z, Lai JM, Tang XF, Lu J, Liu ZW, Wang TY (2007) Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation. Zhonghua Er Ke Za Zhi 45(11):809–813PubMed Wu FQ, Luan Z, Lai JM, Tang XF, Lu J, Liu ZW, Wang TY (2007) Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation. Zhonghua Er Ke Za Zhi 45(11):809–813PubMed
10.
go back to reference Tyndall A (2012) Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. Pediatr Res 71(4 Pt 2):433–438PubMedCrossRef Tyndall A (2012) Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. Pediatr Res 71(4 Pt 2):433–438PubMedCrossRef
11.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
12.
go back to reference Gladman DD, Ibañez D (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed Gladman DD, Ibañez D (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed
13.
go back to reference Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530PubMedCrossRef Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530PubMedCrossRef
14.
go back to reference Li H, Ji CY, Zong XN, Zhang YQ (2009) Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi 47(7):487–492PubMed Li H, Ji CY, Zong XN, Zhang YQ (2009) Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi 47(7):487–492PubMed
15.
16.
17.
go back to reference Petri M, Jones RJ, Bmdsky RA (2003) High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48:166–173PubMedCrossRef Petri M, Jones RJ, Bmdsky RA (2003) High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48:166–173PubMedCrossRef
18.
go back to reference Gladstone DE, Presturd AA, Pradhan A et al (2002) High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 11:405–410PubMedCrossRef Gladstone DE, Presturd AA, Pradhan A et al (2002) High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 11:405–410PubMedCrossRef
19.
go back to reference van Bekkum DW (2003) Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 32(Suppl 1):S37–S39PubMedCrossRef van Bekkum DW (2003) Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 32(Suppl 1):S37–S39PubMedCrossRef
20.
go back to reference Pavletic SZ, Illei GG (2005) The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 19(5):839–858PubMedCrossRef Pavletic SZ, Illei GG (2005) The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 19(5):839–858PubMedCrossRef
21.
go back to reference Brunner HI, Gladman DD (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58(2):556–562PubMedCrossRef Brunner HI, Gladman DD (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58(2):556–562PubMedCrossRef
22.
go back to reference Papadimitraki ED, Isenberg DA (2009) Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 5:391–403PubMedCrossRef Papadimitraki ED, Isenberg DA (2009) Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 5:391–403PubMedCrossRef
23.
go back to reference Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, Smogorzewska M, Koup RA, Betts MR, Collins RH, Douek DC (2001) Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97(5):1458–1466PubMedCrossRef Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, Smogorzewska M, Koup RA, Betts MR, Collins RH, Douek DC (2001) Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97(5):1458–1466PubMedCrossRef
24.
go back to reference Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L, Martini A, Ravelli A (2007) Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 16(8):587–592PubMedCrossRef Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L, Martini A, Ravelli A (2007) Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 16(8):587–592PubMedCrossRef
25.
go back to reference Sreedharan A, Bowyer S, Wallace CA, Robertson MJ, Schmidt K, Woolfrey AE, Nelson RP Jr (2006) Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant 37(7):629–634PubMedCrossRef Sreedharan A, Bowyer S, Wallace CA, Robertson MJ, Schmidt K, Woolfrey AE, Nelson RP Jr (2006) Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant 37(7):629–634PubMedCrossRef
Metadata
Title
Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus
Authors
Gaixiu Su
Zuo Luan
Fengqi Wu
Xinning Wang
Xiangfeng Tang
Nanhai Wu
Kai Wang
Publication date
01-12-2013
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2324-1

Other articles of this Issue 12/2013

Clinical Rheumatology 12/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.